Brolucizumab 3 mg/50 μL

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Neovascular Age-Related Macular Degeneration

Drug Information

Target Indication

Neovascular Age-Related Macular Degeneration

Clinical Trial

Last updated: 12/27/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Related Pipeline

Acute Otitis Media

Endogenous Anterior Uveitis

Allergic Conjunctivitis

Allergic Conjunctivitis

Glaucoma, Open-angle